...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>BMC Neurology >Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology
【24h】

Study protocol of the DUtch PARkinson Cohort (DUPARC): a prospective, observational study of de novo Parkinson’s disease patients for the identification and validation of biomarkers for Parkinson’s disease subtypes, progression and pathophysiology

机译：荷兰帕金森队队列（Duparc）的研究协议：De Novo Parkinson病患者鉴定和验证帕金森病亚型，进展和病理生理学生物标志物鉴定和验证的前瞻性观察研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Parkinson’s Disease (PD) is a heterogeneous, progressive neurodegenerative disorder which is characterized by a variety of motor and non-motor symptoms. To date, no disease modifying treatment for PD exists. Here, the study protocol of the Dutch Parkinson Cohort (DUPARC) is described. DUPARC is a longitudinal cohort study aimed at deeply phenotyping de novo PD patients who are treatment-na?ve at baseline, to discover and validate biomarkers for PD progression, subtypes and pathophysiology. DUPARC is a prospective cohort study in which 150 de novo PD subjects will be recruited through a collaborative network of PD treating neurologists in the northern part of the Netherlands (Parkinson Platform Northern Netherlands, PPNN). Participants will receive follow-up assessments after 1?year and 3?years, with the intention of an extended follow-up with 3?year intervals. Subjects are extensively characterized to primarily assess objectives within three major domains of PD: cognition, gastrointestinal function and vision. This includes brain magnetic resonance imaging (MRI); brain cholinergic PET-imaging with fluoroethoxybenzovesamicol (FEOBV-PET); brain dopaminergic PET-imaging with fluorodopa (FDOPA-PET); detailed neuropsychological assessments, covering all cognitive domains; gut microbiome composition; intestinal wall permeability; optical coherence tomography (OCT); genotyping; motor and non-motor symptoms; overall clinical status and lifestyle factors, including a dietary assessment; storage of blood and feces for additional analyses of inflammation and metabolic parameters. Since the start of the inclusion, at the end of 2017, over 100 PD subjects with a confirmed dopaminergic deficit on FDOPA-PET have been included. DUPARC is the first study to combine data within, but not limited to, the non-motor domains of cognition, gastrointestinal function and vision in PD subjects over time. As a de novo PD cohort, with treatment na?ve subjects at baseline, DUPARC provides a unique opportunity for biomarker discovery and validation without the possible confounding influences of dopaminergic medication. NCT04180865; registered retrospectively, November 28th 2019.
机译：帕金森病（PD）是一种异质，进行的神经变性障碍，其特征在于各种电机和非运动症状。迄今为止，不存在对PD进行修饰治疗的疾病。这里，描述了荷兰帕金森队队列（Duparc）的研究方案。 Duparc是一个纵向队列研究，旨在深入表型患者在基线上进行治疗 - Na'Ve的eNovo Pd患者，发现和验证PD进展，亚型和病理生理学的生物标志物。 Duparc是一项潜在的队列研究，其中将通过在荷兰北部的PD治疗神经科医生的合作网络（Parkinson平台，PPNN）招募150 de Novo PD科目。与会者将在1年和3年后收到后续评估，目的是延长随访3？年间隔。受试者被广泛的特征是主要评估PD：认知，胃肠功能和视力的三个主要结构域内的目标。这包括脑磁共振成像（MRI）;脑胆碱能宠物成像用氟乙氧基异甲胺醇（Feobv-PET）;脑多巴胺能宠物成像与氟德罗德（FDOPA-PET）;详细的神经心理学评估，涵盖所有认知结构域;肠道微生物组成;肠壁渗透率;光学相干断层扫描（OCT）;基因分型;电机和非运动症状;整体临床地位和生活方式因素，包括饮食评估;血液和粪便储存，以进行炎症和代谢参数的额外分析。由于纳入的开始，在2017年底，已包括超过100种PD受试者对FDOPA-PET上的多巴胺能缺陷的影响。 Duparc是第一研究，将数据组合在一起，但不限于PD受试者的认知，胃肠功能和视觉的非运动结构域。作为De Novo PD队列，在基线的治疗Na ve受试者，Duparc为生物标志物发现和验证提供了独特的机会，而无需多巴胺能药物可能的混淆影响。 NCT04180865;注册回顾性，2019年11月28日。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号